Day One Biopharmaceuticals (NASDAQ:DAWN) PT Raised to $40.00 at Piper Sandler

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) had its price objective raised by Piper Sandler from $35.00 to $40.00 in a research note released on Monday, The Fly reports. They currently have an overweight rating on the stock.

Separately, Wedbush boosted their target price on Day One Biopharmaceuticals from $32.00 to $35.00 and gave the company an outperform rating in a research note on Monday, June 13th.

Shares of DAWN stock opened at $17.45 on Monday. The stock’s fifty day simple moving average is $9.50 and its 200-day simple moving average is $12.27. Day One Biopharmaceuticals has a 1-year low of $5.44 and a 1-year high of $28.70.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.09). On average, equities research analysts anticipate that Day One Biopharmaceuticals will post -2.05 EPS for the current year.

In other news, insider Samuel C. Blackman sold 50,000 shares of the company’s stock in a transaction dated Wednesday, June 15th. The stock was sold at an average price of $16.26, for a total transaction of $813,000.00. Following the completion of the sale, the insider now owns 1,316,718 shares in the company, valued at approximately $21,409,834.68. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Ai Day1 Llc purchased 1,200,000 shares of the firm’s stock in a transaction dated Friday, June 17th. The shares were bought at an average price of $15.00 per share, with a total value of $18,000,000.00. Following the purchase, the insider now owns 10,684,638 shares in the company, valued at approximately $160,269,570. The disclosure for this purchase can be found here.

Several institutional investors and hedge funds have recently added to or reduced their stakes in DAWN. Millennium Management LLC acquired a new position in shares of Day One Biopharmaceuticals during the 3rd quarter worth about $4,223,000. Pathway Capital Management LP acquired a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth about $4,082,000. Geode Capital Management LLC lifted its position in shares of Day One Biopharmaceuticals by 434.2% during the 3rd quarter. Geode Capital Management LLC now owns 186,627 shares of the company’s stock worth $4,428,000 after purchasing an additional 151,692 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its position in shares of Day One Biopharmaceuticals by 28.7% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 2,202,533 shares of the company’s stock worth $37,113,000 after purchasing an additional 491,803 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Day One Biopharmaceuticals by 5.7% during the 4th quarter. Northern Trust Corp now owns 103,677 shares of the company’s stock worth $1,747,000 after purchasing an additional 5,578 shares during the last quarter. Institutional investors own 79.02% of the company’s stock.

About Day One Biopharmaceuticals (Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Featured Articles

The Fly logo

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.